Despite elucidating most of the effects of mTOR inhibitors in laboratory experiments, which of those potential mechanisms of action account for the most overall efficacy in patients, to what extent those effects are specific of renal tumour cell biology, and which of the multiple cell signal changes in cancer cells may serve as markers allowing better selection of tumour for efficacy is poorly known. This evidence concerns the gene MTOR and cancer.